Valneva SE (VALN) Interest Expenses (2021 - 2026)
Valneva SE (VALN) posted Interest Expenses of -$6.0 million for Q1 2026, down 120.82% sequentially from $28.6 million in Q4 2025, and up 5.21% YoY from -$5.7 million in Q1 2025.
Analysis
Valneva SE (VALN) Interest Expenses (2021 - 2026) Analysis & Trends
Valneva SE has reported Interest Expenses for 7 years, with the latest figure at -$6.0 million in Q1 2026.
- Quarterly Interest Expenses rose 5.21% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.1 million (up 93.34% YoY) and the FY2025 annual result came in at $48.8 million, up 87.76% from the prior year.
- Interest Expenses declined to -$6.0 million in Q1 2026 per VALN's latest filing, from $28.6 million in the prior quarter.
- Over five years, Interest Expenses peaked at $5.8 billion in Q3 2023 and troughed at -$5.8 billion in Q2 2023.
- A 5-year average of $6.5 million and a median of -$3.7 million in 2022 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 111145.84% in 2023, down 156679.69% in 2023.
- Over 5 years, Interest Expenses stood at $33.1 million in 2022, then grew by 4.29% to $34.5 million in 2023, then sank by 80.5% to $6.7 million in 2024, then surged by 325.35% to $28.6 million in 2025, then tumbled by 120.82% to -$6.0 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$6.0 million, $28.6 million, and $33.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Valneva SE | 581.90 Mn | 440.64 Mn | 1.86 Mn | -6.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.04 Mn |
| Mar 31, 2026 | -5.96 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Sep 30, 2025 | 33.77 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 32.60 Mn |
| Jun 30, 2024 | -5.32 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Dec 31, 2023 | -11.67 Mn |
| Sep 30, 2023 | -3.92 Mn |
| Jun 30, 2023 | -4.12 Mn |
| Mar 31, 2023 | -5.47 Mn |
| Dec 31, 2022 | -5.77 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -3.71 Mn |
| Mar 31, 2022 | -5.30 Mn |
| Dec 31, 2021 | -5.52 Mn |
| Sep 30, 2021 | -4.37 Mn |